Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma

Girolamo Ranieri, Maria Mammì, Eugenio Donato Di Paola, Emilio Russo, Luca Gallelli, Rita Citraro, Cosmo Damiano Gadaleta, Ilaria Marech, Michele Ammendola, Giovambattista De Sarro

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Soft tissue sarcomas (STS) are rare tumors with mesenchymal origin, accounting for 1% of all human cancer. Local control of STS can be obtained through the use of surgery and radiotherapy. In about 40% of these patients, disease will recur at distant sites, and of these more than 90% will die because of this aggressive malignancy. In advanced and/or metastatic STS patients treated with anthracycline-based regimen the median overall survival is about 12 months, and it has remained unchanged during the last 20 years. Clearly, this strongly suggests the need for discover more active compounds in STS, such as imatinib in GIST or dermatofibrosarcoma patients. In this paper we describe the crucial role of angiogenesis mechanisms in sarcomas development and progression. Consequentially, we focus on pazopanib, a novel multitargeted tyrosine kinase inhibitor with anti-angiogenic activity, mainly due to VEGFR2 pathway interference. We also analyze principal completed trials leading pazopanib approval in sarcomas pretreated patients.

Original languageEnglish
Pages (from-to)322-329
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume89
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Sarcoma
Protein-Tyrosine Kinases
Therapeutics
Dermatofibrosarcoma
Neoplasms
Anthracyclines
pazopanib
Radiotherapy
Survival

Keywords

  • Angiogenesis
  • Pazopanib
  • Soft tissue sarcoma
  • Targeted therapy
  • Tyrosine kinase inhibitor (TKI)
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity : A new treatment for metastatic soft tissue sarcoma. / Ranieri, Girolamo; Mammì, Maria; Donato Di Paola, Eugenio; Russo, Emilio; Gallelli, Luca; Citraro, Rita; Gadaleta, Cosmo Damiano; Marech, Ilaria; Ammendola, Michele; De Sarro, Giovambattista.

In: Critical Reviews in Oncology/Hematology, Vol. 89, No. 2, 02.2014, p. 322-329.

Research output: Contribution to journalArticle

Ranieri, Girolamo ; Mammì, Maria ; Donato Di Paola, Eugenio ; Russo, Emilio ; Gallelli, Luca ; Citraro, Rita ; Gadaleta, Cosmo Damiano ; Marech, Ilaria ; Ammendola, Michele ; De Sarro, Giovambattista. / Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity : A new treatment for metastatic soft tissue sarcoma. In: Critical Reviews in Oncology/Hematology. 2014 ; Vol. 89, No. 2. pp. 322-329.
@article{17e5c584135842ec9e19e50027f1ca1c,
title = "Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma",
abstract = "Soft tissue sarcomas (STS) are rare tumors with mesenchymal origin, accounting for 1{\%} of all human cancer. Local control of STS can be obtained through the use of surgery and radiotherapy. In about 40{\%} of these patients, disease will recur at distant sites, and of these more than 90{\%} will die because of this aggressive malignancy. In advanced and/or metastatic STS patients treated with anthracycline-based regimen the median overall survival is about 12 months, and it has remained unchanged during the last 20 years. Clearly, this strongly suggests the need for discover more active compounds in STS, such as imatinib in GIST or dermatofibrosarcoma patients. In this paper we describe the crucial role of angiogenesis mechanisms in sarcomas development and progression. Consequentially, we focus on pazopanib, a novel multitargeted tyrosine kinase inhibitor with anti-angiogenic activity, mainly due to VEGFR2 pathway interference. We also analyze principal completed trials leading pazopanib approval in sarcomas pretreated patients.",
keywords = "Angiogenesis, Pazopanib, Soft tissue sarcoma, Targeted therapy, Tyrosine kinase inhibitor (TKI), Vascular endothelial growth factor (VEGF)",
author = "Girolamo Ranieri and Maria Mamm{\`i} and {Donato Di Paola}, Eugenio and Emilio Russo and Luca Gallelli and Rita Citraro and Gadaleta, {Cosmo Damiano} and Ilaria Marech and Michele Ammendola and {De Sarro}, Giovambattista",
year = "2014",
month = "2",
doi = "10.1016/j.critrevonc.2013.08.012",
language = "English",
volume = "89",
pages = "322--329",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity

T2 - A new treatment for metastatic soft tissue sarcoma

AU - Ranieri, Girolamo

AU - Mammì, Maria

AU - Donato Di Paola, Eugenio

AU - Russo, Emilio

AU - Gallelli, Luca

AU - Citraro, Rita

AU - Gadaleta, Cosmo Damiano

AU - Marech, Ilaria

AU - Ammendola, Michele

AU - De Sarro, Giovambattista

PY - 2014/2

Y1 - 2014/2

N2 - Soft tissue sarcomas (STS) are rare tumors with mesenchymal origin, accounting for 1% of all human cancer. Local control of STS can be obtained through the use of surgery and radiotherapy. In about 40% of these patients, disease will recur at distant sites, and of these more than 90% will die because of this aggressive malignancy. In advanced and/or metastatic STS patients treated with anthracycline-based regimen the median overall survival is about 12 months, and it has remained unchanged during the last 20 years. Clearly, this strongly suggests the need for discover more active compounds in STS, such as imatinib in GIST or dermatofibrosarcoma patients. In this paper we describe the crucial role of angiogenesis mechanisms in sarcomas development and progression. Consequentially, we focus on pazopanib, a novel multitargeted tyrosine kinase inhibitor with anti-angiogenic activity, mainly due to VEGFR2 pathway interference. We also analyze principal completed trials leading pazopanib approval in sarcomas pretreated patients.

AB - Soft tissue sarcomas (STS) are rare tumors with mesenchymal origin, accounting for 1% of all human cancer. Local control of STS can be obtained through the use of surgery and radiotherapy. In about 40% of these patients, disease will recur at distant sites, and of these more than 90% will die because of this aggressive malignancy. In advanced and/or metastatic STS patients treated with anthracycline-based regimen the median overall survival is about 12 months, and it has remained unchanged during the last 20 years. Clearly, this strongly suggests the need for discover more active compounds in STS, such as imatinib in GIST or dermatofibrosarcoma patients. In this paper we describe the crucial role of angiogenesis mechanisms in sarcomas development and progression. Consequentially, we focus on pazopanib, a novel multitargeted tyrosine kinase inhibitor with anti-angiogenic activity, mainly due to VEGFR2 pathway interference. We also analyze principal completed trials leading pazopanib approval in sarcomas pretreated patients.

KW - Angiogenesis

KW - Pazopanib

KW - Soft tissue sarcoma

KW - Targeted therapy

KW - Tyrosine kinase inhibitor (TKI)

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=84892505431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892505431&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.08.012

DO - 10.1016/j.critrevonc.2013.08.012

M3 - Article

C2 - 24041629

AN - SCOPUS:84892505431

VL - 89

SP - 322

EP - 329

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -